| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. This medicine was considered by AWMSG Scrutiny Panel on 7th August 2025. It was considered not suitable for assessment by LOWMAG (AWTTC ref 7160). |
|
Medicine details |
|
| Medicine name | pegylated liposomal irinotecan (Onivyde®) |
| Formulation | 5.0 mg/ml concentrate for solution for infusion |
| Reference number | 1630 |
| Indication | Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/08/2016 |
| NICE guidance | TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Further information This medicine was considered by AWMSG scrutiny panel on 7th August 2025. Pegylated liposomal irinotecan (Onivyde®) in conjunction with chemotherapy after progression on gemcitabine-based therapy is not suitable for assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). There were no significant new factors which would change the original NICE decision. |
|